This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Radiotherapy treatments

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Radiotherapy is the treatment of choice in patients with stage IIB, III and IV disease, and most patients with stage IIA disease. Stage IB tumours may be treated by radiotherapy if the lesion is of sufficient size that extensive surgical resection is required, with consequent increased risk of postoperative bladder dysfunction.

Stages I, II, and III are usually treated with a combination intracavity radioisotope and high-energy external radiation therapy, for example caesium-137.

Stage IV is treated by external radiotherapy if the disease is confined to the pelvis. Spread outside the pelvis is an indication for chemotherapy.

Complications of radiotherapy may include:

  • fatigue and diarrhoea during treatment; the diarrhoea may persist after the treatment is completed
  • proctitis, cystitis and rarely, fistula formation
  • vaginitis and dyspareunia
  • vaginal stenosis - rare if dilators used regularly during treatment
  • loss of ovarian function - may necessitate HRT to overcome abrupt onset of menopausal symptoms in premenopausal women

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.